JAZZ News and Press, Jazz Pharmaceuticals plc From 02/09/21

Jazz Pharmaceuticals (NASDAQ: JAZZ) recently announced plans to acquire cannabinoid-focused biotech GW Pharmaceuticals (NASDAQ: GWPH) in a deal valued at $7.2 billion. In this Motley Fool Live video recorded on Feb. 3 , Fool.com writers Keith Speights and Brian Orell...

After a two-year dark night, a new dawn is here for cannabis investors. Cannabis companies have stronger fundamentals that will drive the sector higher over the next five years. Investors can now have more clarity about which companies have the greatest potential for growth. ...

One of the biggest names in cannabis-based novel medicine announced this week that it will be acquired by a fellow pharmaceutical player. Also this week, new numbers show that Canadian sales of legal cannabis are overtaking sales of unregulated products in the country. ...

Top Cannabis Stocks And Market Performance In the first week of February, marijuana stocks continue increasing in the market adding to gains from January. One acquisition occurring last week could have been a big influence on the market. In detail, Jazz Pharmaceuticals plc ( NASDA...

On Wednesday, Jazz Pharmaceuticals (JAZZ) said it would acquire GW Pharma (GWPH) in a $7.2B deal.Acquisition gives Jazz access to GW's cannibinoid drug for seizures, Epidiolex, as well as other cannibinoid-based therapies in the pipeline.Several other biopharmas are exploring cannibinoid trea...

Pot investors are hardly strangers to splashy mergers and acquisitions. And following the big news about Aphria and Tilray combining their companies , there's a new deal that's making waves in the cannabis sector. On Wednesday, Jazz Pharmaceuticals (NASDAQ: JAZZ) announc...

Stock market indices rallied every day for their best week since early November as coronavirus vaccine news swayed investors' mood. The Nasdaq (COMP) leads major indices with 5% gains for the week. The broader S&P 500 (SP500) is up about 4% for the week, with the Dow Industrials (DJI) add...

Jazz made a bold bet with the acquisition of GW Pharmaceuticals. The deal brings a potential blockbuster Epidiolex and a nascent cannabinoid-based pipeline. Jazz's dependence on Xyrem should reduce substantially. Increased debt is a potential risk. For further details se...

Jazz Pharmaceuticals (NASDAQ: JAZZ) was out of tune with the biotech investment community -- not to mention its own shareholders -- for much of last year. Indeed, its stock has lagged behind the S&P 500 , with an annual return of 6.8% compared to the index's 18...

High-scoring, high short-interest stocks that can benefit from ongoing short covering by hedge funds as they reduce single stock risk. Institutional quality stocks with potential catalysts that support ongoing short covering, rather than flash-in-the-pan volatility. Ideas across a...